Lukas Chinczewski

No ORCID on file · 13 papers in corpus · active 2025-2026

Study types

  • article 9
  • other 3

Condition tags

  • endometriosis 12
article 2026
Additional file 1 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048940

Supplementary Material 1.

article 2026
Additional file 1 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048940.v1

Supplementary Material 1.

article 2026
Additional file 2 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048943.v1

Supplementary Material 2.

article 2026
Additional file 2 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048943

Supplementary Material 2.

article 2026
Additional file 3 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048946

Supplementary Material 3.

article 2026
Additional file 3 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048946.v1

Supplementary Material 3.

article 2026
Additional file 4 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048949.v1

Supplementary Material 4.

article 2026
Additional file 4 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048949

Supplementary Material 4.

article 2026
Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors
·doi:10.1016/j.ijgc.2025.103753
other 2026
Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.c.8428212.v1

Abstract Background Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis indepe…

other 2026
Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.c.8428212

Abstract Background Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis indepe…

other 2026
Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
BMC cancer ·doi:10.1186/s12885-026-15980-w

BACKGROUND: Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis independently …

2025
The Charité protocol for surveillance, treatment and after-care management in women with Lynch syndrome.
Archives of gynecology and obstetrics ·doi:10.1007/s00404-025-08112-5

BackgroundLynch syndrome (LS) is the most common inherited cancer syndrome, caused by germline mutations in mismatch repair (MMR) genes such as MLH1, MSH2, MSH6, and PMS2. While primarily associated with colorectal cancer, LS significantly …